IT1270123B - Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia - Google Patents

Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Info

Publication number
IT1270123B
IT1270123B ITMI942025A ITMI942025A IT1270123B IT 1270123 B IT1270123 B IT 1270123B IT MI942025 A ITMI942025 A IT MI942025A IT MI942025 A ITMI942025 A IT MI942025A IT 1270123 B IT1270123 B IT 1270123B
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
therapy
compositions containing
containing engineered
engineered microorganisms
Prior art date
Application number
ITMI942025A
Other languages
English (en)
Inventor
Aldo Tagliabue
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Priority to ITMI942025A priority Critical patent/IT1270123B/it
Publication of ITMI942025A0 publication Critical patent/ITMI942025A0/it
Priority to PCT/EP1995/003921 priority patent/WO1996011277A1/en
Priority to EP95935431A priority patent/EP0784689A1/en
Priority to AU37453/95A priority patent/AU3745395A/en
Priority to CA002201721A priority patent/CA2201721A1/en
Priority to JP8512318A priority patent/JPH10506791A/ja
Publication of ITMI942025A1 publication Critical patent/ITMI942025A1/it
Application granted granted Critical
Publication of IT1270123B publication Critical patent/IT1270123B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Vengono descritte composizioni farmaceutiche per la somministrazione locale di proteine ricombinanti farmacologicamente attive, contenenti ceppi batterici ingegnerizzati, capaci di colonizzare le superfici mucosali e di produrre localmente la proteina ricombinante di interesse. Si prevede la possibilità di usare batteri con diverse capacità di colonizzazione per la somministrazione localizzata di entità farmacologicamente attive in diversi siti anatomici.
ITMI942025A 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia IT1270123B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
PCT/EP1995/003921 WO1996011277A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
EP95935431A EP0784689A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
AU37453/95A AU3745395A (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
CA002201721A CA2201721A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
JP8512318A JPH10506791A (ja) 1994-10-05 1995-10-04 治療用送達系としての微生物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Publications (3)

Publication Number Publication Date
ITMI942025A0 ITMI942025A0 (it) 1994-10-05
ITMI942025A1 ITMI942025A1 (it) 1996-04-05
IT1270123B true IT1270123B (it) 1997-04-28

Family

ID=11369649

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Country Status (6)

Country Link
EP (1) EP0784689A1 (it)
JP (1) JPH10506791A (it)
AU (1) AU3745395A (it)
CA (1) CA2201721A1 (it)
IT (1) IT1270123B (it)
WO (1) WO1996011277A1 (it)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1999013053A1 (en) 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
PT1194554E (pt) * 1999-07-05 2007-01-31 Vlaams Interuniv Inst Biotech Libertação de péptidos trifólios
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
JP2004505113A (ja) * 2000-07-27 2004-02-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 単純疱疹ウイルス糖蛋白質ｄを用いた組成物及びそれを用いて免疫応答を抑制する方法
US20020054865A1 (en) 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2003063786A2 (en) * 2002-01-31 2003-08-07 Symbigene, Inc. Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
AU2003276822A1 (en) 2002-03-08 2004-02-02 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
DE60319822T2 (de) 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
US7754467B2 (en) 2003-01-29 2010-07-13 Osel, Inc. Surface expression of biologically active proteins in bacteria
WO2006036406A2 (en) 2004-08-25 2006-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Live microbial microbicides
ATE474596T1 (de) 2004-09-10 2010-08-15 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
US7456011B2 (en) 2005-01-12 2008-11-25 Osel, Inc. Modified cyanovirin-n polypeptide
AU2006319216B2 (en) 2005-11-29 2012-09-13 Intrexon Actobiotics Nv Induction of mucosal tolerance to antigens
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
EP2115146B1 (en) 2007-01-12 2016-07-06 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
DK3181682T3 (da) 2008-09-29 2021-07-05 Intrexon Actobiotics Nv Reduceret kolonisering af mikrober på slimhinden
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
WO2011039137A1 (en) 2009-09-29 2011-04-07 Actogenix N.V. Lactobacillus and streptococcus promoters and uses thereof
CA2786847C (en) 2010-01-14 2017-08-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs)
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
US9476056B2 (en) 2010-05-12 2016-10-25 Universite De Rennes 1 Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof
EP2582387A2 (en) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Compositions and methods for treating inflammatory conditions
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
WO2013041672A1 (en) 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
EP3382006B1 (en) 2011-09-23 2021-02-17 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
US9234204B2 (en) 2012-08-07 2016-01-12 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
KR20170019427A (ko) 2014-06-17 2017-02-21 탑제닉스, 인크. Ｕｖ 차단을 위한 국소용 제형
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
PL3921422T3 (pl) 2019-03-04 2024-04-02 Aurealis Therapeutics AG Indukowalny chlorkiem prokariotyczny układ ekspresji

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321962C (en) * 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations

Also Published As

Publication number Publication date
CA2201721A1 (en) 1996-04-18
JPH10506791A (ja) 1998-07-07
WO1996011277A1 (en) 1996-04-18
ITMI942025A0 (it) 1994-10-05
ITMI942025A1 (it) 1996-04-05
EP0784689A1 (en) 1997-07-23
AU3745395A (en) 1996-05-02

Similar Documents

Publication Publication Date Title
IT1270123B (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
BR9507752A (pt) Cepas de lactobacilos de origem humanan suas composições e seus usos
WO1998040401A3 (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
AU2845599A (en) Pharmaceutical compositions and their use
IL115970A (en) 6-Arylpyrido [2,3-d] pyrimidin-2- and 3-aryl-1, 6-naphthyridin-7-amines and pharmaceutical compositions containing them
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
DE69839699D1 (de) Vaginales lactobacillus-medikament
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
AU1937395A (en) Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
IL156942A0 (en) Compounds, pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
AU694270B2 (en) Biologically active silicon compounds and their therapeutic and cosmetic applications
AU1384995A (en) Human circulating cytokine cc-1
WO2003087353A3 (en) Purified polypeptides involved in membrane biogenesis
SG142165A1 (en) Biologically active peptides
AUPN907296A0 (en) Biocontrol agents for use in treatment of opportunistic infections
IT1252160B (it) Composizioni farmaceutiche contenenti il peptidoglicano del lactobacillus casei
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
ATE294802T1 (de) 3-alkylimidazopyridine
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
CA2114629A1 (en) Receptor conjugates for targeting antibiotics to bacteria
WO2003025004A3 (en) Purified bacterial polypeptides involved in nucleic acid processing

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971029